The subjects should voluntarily enroll and sign the informed consent form, and agree to follow the trial treatment regimen and visit schedule.

Male or female, 18-75 years old (including boundary values).

Patients with histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC), metastatic, or recurrent (Stage IV) non-squamous NSCLC who are unable to receive surgical treatment or radical concurrent radiochemotherapy according to the TNM Staging of Lung Cancer (8th Edition) of the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC).

Patients have at least one imaging measurable lesion according to RECIST v1.1. Note: the measurable lesions should neither be treated locally with radiotherapy nor biopsied during the screening period; if there is only one measurable lesion, biopsy of that lesion is permitted, but baseline imaging examination of that lesion should be performed at least 14 days after biopsy.

Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

Expected survival ≥ 12 weeks.